Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-11-03 Sale |
2023-11-06 4:42 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
8,026 | $13.08 | $104,999 | 1,589,111 (Indirect Direct) |
View |
| 2023-09-29 Sale |
2023-10-03 7:40 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
12,000 | $13.62 | $163,498 | 1,449,585 (Indirect Direct) |
View |
| 2023-09-26 Sale |
2023-09-28 4:27 pm |
Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH Schwab Andrew J. 10% Owner |
197,500 | $15 | $2,962,500 | 854,796 (Indirect) |
View |
| 2023-09-25 Sale |
2023-09-26 7:37 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $13.81 | $165,691 | 1,597,137 (Indirect Direct) |
View |
| 2023-08-24 Sale |
2023-08-28 4:20 pm |
Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH Schwab Andrew J. 10% Owner |
440,000 | $16 | $7,040,000 | 887,507 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-11-03 Exercise |
2023-11-06 4:42 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
8,026 | $0 | 1,589,111 (Direct) |
View |
| 2023-11-03 Exercise |
2023-11-06 4:42 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
8,026 | $1.12 | 1,589,111 (Direct) |
View |
| 2023-09-29 Exercise |
2023-10-03 7:40 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
12,000 | $0 | 1,449,585 (Direct) |
View |
| 2023-09-29 Exercise |
2023-10-03 7:40 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
12,000 | $1.12 | 1,449,585 (Direct) |
View |
| 2023-09-25 Exercise |
2023-09-26 7:37 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $0 | 1,597,137 (Direct) |
View |
| 2023-09-25 Exercise |
2023-09-26 7:37 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $1.12 | 1,597,137 (Direct) |
View |
| 2023-05-17 Exercise |
2023-05-19 4:19 pm |
N/A 2032-06-01 |
Enliven Therapeutics Inc. | ELVN | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director 10% Owner |
2,125 | $0 | 8,951,463 (Indirect) |
View |
| 2023-05-17 Exercise |
2023-05-19 4:19 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director 10% Owner |
2,125 | $4.28 | 8,951,463 (Indirect) |
View |
| 2023-05-17 Exercise |
2023-05-19 4:12 pm |
N/A 2032-06-01 |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
2,125 | $0 | 8,951,463 (Indirect) |
View |
| 2023-05-17 Exercise |
2023-05-19 4:12 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
2,125 | $4.28 | 8,951,463 (Indirect) |
View |
| 2023-04-04 Option Award |
2023-04-06 8:34 pm |
N/A 2033-04-04 |
Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer |
206,000 | $0 | 206,000 (Direct) |
View |
| 2023-04-04 Option Award |
2023-04-06 8:33 pm |
N/A 2033-04-04 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
206,000 | $0 | 206,000 (Direct) |
View |
| 2023-04-04 Option Award |
2023-04-06 8:32 pm |
N/A 2033-04-04 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
206,000 | $0 | 206,000 (Direct) |
View |
| 2023-04-04 Option Award |
2023-04-06 8:32 pm |
N/A 2033-04-04 |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise Chief Medical Officer |
206,000 | $0 | 206,000 (Direct) |
View |
| 2023-04-04 Option Award |
2023-04-06 8:30 pm |
N/A 2033-04-04 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
452,000 | $0 | 452,000 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:22 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Schwab Andrew J. Director 10% Owner |
27,567 | $0 | 27,567 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:20 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director |
27,567 | $0 | 27,567 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:19 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
34,458 | $0 | 34,458 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:18 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
27,567 | $0 | 27,567 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:17 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director |
27,567 | $0 | 27,567 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:16 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Bauer Jake Director |
27,567 | $0 | 27,567 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:15 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
27,567 | $0 | 27,567 (Direct) |
View |
Ownership |
2023-03-06 5:18 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH 10% Owner |
0 | $0 | 5,798,475 (Indirect) |
View |
| 2023-02-23 Option Award |
2023-02-27 9:55 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Schwab Andrew J. Director |
5,798,475 | $0 | 960,383 (Indirect) |
View |
| 2023-02-23 Option Award |
2023-02-27 9:54 pm |
N/A 2032-08-12 |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
239,056 | $0 | 201,649 (Direct) |
View |
| 2023-02-23 Option Award |
2023-02-27 9:53 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
7,899,572 | $0 | 288,114 (Indirect) |
View |
| 2023-02-23 Option Award |
2023-02-27 9:51 pm |
N/A 2032-08-12 |
Enliven Therapeutics Inc. | ELVN | Bauer Jake Director |
105,078 | $0 | 105,078 (Direct) |
View |
| 2023-02-23 Option Award |
2023-02-27 9:43 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director |
87,373 | $0 | 87,373 (Direct) |
View |
| 2023-02-23 Option Award |
2023-02-27 9:35 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer |
519,963 | $0 | 519,963 (Direct) |
View |
| 2023-02-23 Option Award |
2023-02-27 9:34 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
1,550,116 | $0 | 1,550,116 (Direct) |
View |
| 2023-02-23 Option Award |
2023-02-27 9:33 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
262,120 | $0 | 262,120 (Direct) |
View |
| 2023-02-23 Option Award |
2023-02-27 9:33 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
1,924,969 | $0 | 837,444 (Direct) |
View |
| 2023-02-23 Option Award |
2023-02-27 9:32 pm |
N/A 2031-06-17 |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise Chief Medical Officer |
287,084 | $0 | 287,084 (Direct) |
View |